NMN, walking distance and exercise

The human walking trial

I would choose a walking test over a photograph of someone looking invigorated every time. Walking distance gives an experiment a physical outcome to compare. In a multicentre, double-blind, placebo-controlled NMN trial in healthy middle-aged adults, blood NAD+ increased over 60 days and walking distance and quality-of-life scores improved compared with placebo.

That is an encouraging result. It connects a biochemical change with a functional measure within the same trial, rather than asking a reader to imagine the connection. The study also reports a dose-dependent blood NAD+ rise. The walking finding deserves the foreground, in my opinion, even when the chemical measurement is easier to summarise.

The size of an improvement matters to me as well as its direction. A positive comparison gives the experiment a reason to be followed up. Persistence and practical significance would help connect it with everyday stamina. I give this trial considerable credit, while the broader case for human benefit remains limited in the human evidence review.

Prediabetes and muscle metabolism

A different experiment asks a different physical question. Over 10 weeks, NMN improved muscle insulin sensitivity and remodelled insulin signalling in prediabetic, postmenopausal women. Body composition and HbA1c were unchanged.

I am glad those unchanged measurements sit beside the positive finding. They make it possible to appreciate the muscle result without quietly turning it into a claim about body composition or a general change in glucose control. This trial concerns a particular metabolic response in a particular group of women. Walking distance was the outcome in the other trial.

The everyday word energy could accommodate either finding and almost anything else. The experimental language is less accommodating, and more useful. An insulin-response measurement cannot stand in for a reported reduction in fatigue, just as walking farther leaves many questions about the underlying chemistry unanswered. Each experiment has supplied something specific enough to examine.

Exercise intolerance in ANT1-deficient mice

The most vivid exercise mechanism here comes from a very different setting. In ANT1-deficient mice, exercise produced an NAD+ shortfall that stalled the TCA cycle and skeletal-muscle mitochondrial respiration. Nicotinamide riboside treatment raised muscle and liver NAD+ and was associated with increased exercise capacity and mitochondrial respiration. This was a model of mitochondrial myopathy.

A deficiency linked to a stalled metabolic process, followed by restoration and better function: that sequence has considerable force for me. It gives a plausible mechanism room to demonstrate a consequence. It also makes the starting condition impossible to ignore. These mice had a defined defect. They do not represent every tired human being, or even the healthy middle-aged adults in the walking trial.

For me, the starting biology gives the mouse result its particular value. It suggests a useful question for future human work: whether benefit depends on a particular impairment. The experiment itself supplies no human answer to that question.

Tolerability and duration

The 60-day NMN trial reported no safety issues. That is reassuring information about the experiment as conducted. A longer period of use or a different population would be a further question, and the trial's duration cannot answer it by itself.

The human ageing review describes limited efficacy across the field despite consistent blood NAD+ elevation. Against that background, the walking result makes a good case, to my mind, for more work: repeat the functional comparison, investigate the size and persistence of any improvement, and learn who benefits. Those are research questions. An individual decision about fatigue or treatment needs personal medical assessment beyond these pages.